Evidence map›Paper›PMID 42348066›Full record

ArticleJournal of neuro-oncology2026

Long-term outcomes and late effects of surgery and radiotherapy in adult intracranial ependymoma patients.

Olaf N van de Langerijt, Felix Ehret, Andrzej Niemierko, Kevin S Oh, William E Butler, William T Curry, Brian V Nahed, Daphne A Haas-Kogan, Nirav Patel, Ariel E Marciscano and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Olaf N van de LangerijtDepartment of Radiation Oncology, Mass General Brigham Cancer Institute, Boston, MA, 02114, USA.
Felix EhretDepartment of Radiation Oncology, Mass General Brigham Cancer Institute, Boston, MA, 02114, USA.
Andrzej NiemierkoDepartment of Radiation Oncology, Mass General Brigham Cancer Institute, Boston, MA, 02114, USA.
Kevin S OhDepartment of Radiation Oncology, Mass General Brigham Cancer Institute, Boston, MA, 02114, USA.
William E ButlerHarvard Medical School, Boston, MA, 02115, USA.
William T CurryHarvard Medical School, Boston, MA, 02115, USA.
Brian V NahedHarvard Medical School, Boston, MA, 02115, USA.
Daphne A Haas-KoganDepartment of Radiation Oncology, Mass General Brigham Cancer Institute, Boston, MA, 02114, USA.
Nirav PatelHarvard Medical School, Boston, MA, 02115, USA.
Ariel E MarciscanoDepartment of Radiation Oncology, Mass General Brigham Cancer Institute, Boston, MA, 02114, USA.
Rifaquat M RahmanDepartment of Radiation Oncology, Mass General Brigham Cancer Institute, Boston, MA, 02114, USA.
Geert O JanssensDepartment of Radiation Oncology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands.
Helen A ShihDepartment of Radiation Oncology, Mass General Brigham Cancer Institute, Boston, MA, 02114, USA. hshih@mgh.harvard.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate progression-free survival (PFS), overall survival (OS), local control (LC), and radiotherapy-related toxicities in the treatment of adult intracranial ependymoma.

methodsA retrospective analysis was performed of WHO grade 2-3 adult intracranial ependymoma patients (≥ 18 years) treated with surgery alone or surgery and adjuvant radiotherapy between 2000 and 2024. Kaplan-Meier analyses were used to estimate PFS and OS. Acute and late treatment-related toxicities were characterized.

resultsFifty-eight patients met the inclusion criteria. Median age was 39 years (interquartile range [IQR] 25-51), and median follow-up was 51 months (IQR 23-103). Overall, 76% were WHO grade 2, 74% had posterior fossa location, gross total resection was achieved in 60%, 88% received adjuvant local radiotherapy, and 5% received adjuvant chemotherapy. Five and 10-year PFS rates were 80% and 64%, respectively; 5 and 10-year OS rates were 92% and 85%, respectively. There were 13 (22%) recurrences: The location of first failure was local in nine, distant in two, and both local and distant in two. The 5-year LC rate was 82% (95% CI 67-90%), and the 10-year LC rate was 72% (95% CI 53-84%). The median time to local failure was 5.4 years. Ten (22%) patients experienced at least one grade ≥ 2 late treatment-related toxicity. One potential secondary glioma (grade 5) occurred after nine years.

conclusionIn adult patients with intracranial ependymomas, surgery alone or surgery followed by radiotherapy resulted in relatively favorable long-term PFS, OS, and LC. Recurrences and late toxicities remain a concern.

Indexed as

Brain NeoplasmsEpendymomaNeurosurgical ProceduresAdultCombined Modality TherapyFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm Recurrence, LocalRadiotherapy, AdjuvantRetrospective StudiesSurvival RateTreatment OutcomeYoung AdultEpendymomaIntracranialLocal controlRadiation therapySurvivalToxicity

Identifiers

PMID42348066

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.